[Form 4] NOVAVAX INC Insider Trading Activity
Novavax (NVAX) director reported an equity acquisition.
Rhea-AI Filing Summary
Novavax (NVAX) director reported an equity acquisition. On 10/29/2025, the reporting person acquired 3,800 shares of common stock through the settlement of restricted stock units (transaction code M). Following the transaction, the director beneficially owned 28,490 shares directly.
The RSUs were granted under the Company’s Amended and Restated 2015 Stock Incentive Plan and vest in three equal annual installments on each anniversary of the 10/29/2022 grant date, subject to continued employment. The derivative line shows 3,800 RSUs converted at $0.00 with 0 RSUs remaining from this grant after the transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 3,800 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,800 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
- F2. The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the October 29, 2022 grant date, in each case subject to continued employment through such vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NVAX disclose in this Form 4?
What is the RSU vesting schedule mentioned?
What was the derivative security price shown?
Was the transaction coded as an exercise or conversion?
AI-generated analysis. How Rhea-AI works. Not financial advice.